EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
April 11 2008 - 7:00AM
PR Newswire (US)
Oral Presentation During the "New Drugs on the Horizon 2" Special
Session ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ --
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical
company developing therapeutics for the treatment of cancer and
inflammatory diseases, today announced it will present preclinical
data for its product candidates ENMD-2076, MKC-1, and ENMD-1198.
The data will be presented by EntreMed scientists and collaborators
during the American Association for Cancer Research (AACR) Annual
Meeting being held April 12-16, 2008 in San Diego, California.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO ) Mark
R. Bray, Ph.D., EntreMed Vice President, Research, will give an
oral presentation on the Company's selective kinase inhibitor,
ENMD-2076, during the special session, "New Drugs on the Horizon
2." EntreMed will share the podium with representatives from
leading pharmaceutical companies during this special session which
provides early disclosure of new small molecules that are nearing
or have recently advanced into clinical trials. Dr. Bray's
presentation is scheduled for Sunday, April 13, 2008, at 3:15 p.m.
ENMD-2076 is selective kinase inhibitor with potent activity
against Aurora A and tyrosine kinases linked to promoting cancer
and inflammatory diseases. ENMD-2076 acts through multiple pathways
resulting in antiproliferative activity and the inhibition of
angiogenesis. ENMD-2076 has demonstrated substantial,
dose-dependent efficacy as a single agent in multiple xenograft
models, including tumor regression in breast, colon, and leukemia
models. Importantly, ENMD-2076 is an oral agent that has shown an
acceptable toxicity profile in preclinical studies without
cardiovascular effects. In addition, EntreMed scientists are
scheduled for the following poster presentations: -- "ENMD-1198
Antitumor Activity and Inhibition of HIF-1alpha, STAT3 and NFkappaB
Signaling Pathways are Dependent on Microtubule Isotype Expression
and Targeting," Monday, April 14, 2008 from 1:00 PM - 5:00 PM --
"Combination Therapy of MKC-1 and Paclitaxel Synergistically
Inhibits Tumor Growth in the MDA-MB-231 Orthotopic Breast Cancer
Tumor Model," Tuesday, April 15, 2008, 8:00 AM - 12:00 PM. Dr.
Bray's presentation, as well as the poster presentations, will be
available on the Company's web site at http://www.entremed.com/.
About EntreMed EntreMed, Inc. is a clinical-stage pharmaceutical
company developing therapeutic candidates primarily for the
treatment of cancer and inflammation. MKC-1 is currently in
multiple Phase 2 clinical trials for cancer. MKC-1 is an oral
cell-cycle regulator with activity against the mTOR pathway.
ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective
kinase inhibitor, are in Phase 1 studies in advanced cancers. The
Company also has an approved IND application for Panzem(R) in
rheumatoid arthritis. EntreMed's goal is to develop and
commercialize new compounds based on the Company's expertise in
angiogenesis, cell-cycle regulation and inflammation -- processes
vital to the treatment of cancer and other diseases, such as
rheumatoid arthritis. Additional information about EntreMed is
available on the Company's web site at http://www.entremed.com/ and
in various filings with the Securities and Exchange Commission.
Forward Looking Statements This release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act with respect to the outlook for expectations for future
financial or business performance (including the timing of royalty
revenues and future R&D expenditures), strategies, expectations
and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made,
and no duty to update forward-looking statements is assumed. Actual
results could differ materially from those currently anticipated
due to a number of factors, including those set forth in Securities
and Exchange Commission filings under "Risk Factors," including
risks relating to the need for additional capital and the
uncertainty of additional funding; variations in actual sales of
Thalomid(R), risks associated with the Company's product
candidates; the early-stage products under development; results in
preclinical models are not necessarily indicative of clinical
results, uncertainties relating to preclinical and clinical trials;
success in the clinical development of any products; dependence on
third parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed products (such
as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks). CONTACT: Ginny Dunn Associate
Director, Corporate Communications & Investor Relations
EntreMed, Inc. 240.864.2643
http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO
http://photoarchive.ap.org/ DATASOURCE: EntreMed, Inc. CONTACT:
Ginny Dunn, Associate Director, Corporate Communications &
Investor Relations of EntreMed, Inc., +1-240-864-2643 Web site:
http://www.entremed.com/
Copyright